Cognition Therapeutics, Inc. (NASDAQ:CGTX) Shares Purchased by Kestra Advisory Services LLC

Kestra Advisory Services LLC increased its holdings in shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX – Get Rating) by 237.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,618 shares of the company’s stock after purchasing an additional 35,618 shares during the period. Kestra Advisory Services LLC owned 0.17% of Cognition Therapeutics worth $106,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Captrust Financial Advisors acquired a new stake in shares of Cognition Therapeutics in the 3rd quarter worth $95,000. Baird Financial Group Inc. lifted its stake in shares of Cognition Therapeutics by 100.0% in the third quarter. Baird Financial Group Inc. now owns 40,786 shares of the company’s stock valued at $77,000 after purchasing an additional 20,393 shares during the period. State Street Corp acquired a new stake in shares of Cognition Therapeutics in the third quarter valued at about $28,000. Two Sigma Investments LP acquired a new stake in shares of Cognition Therapeutics in the third quarter valued at about $46,000. Finally, Vanguard Group Inc. increased its holdings in Cognition Therapeutics by 465.7% during the 3rd quarter. Vanguard Group Inc. now owns 401,203 shares of the company’s stock valued at $762,000 after acquiring an additional 330,283 shares in the last quarter. Institutional investors and hedge funds own 23.06% of the company’s stock.

Cognition Therapeutics Trading Down 6.6 %

NASDAQ:CGTX opened at $1.56 on Friday. The firm has a 50-day moving average price of $1.77 and a two-hundred day moving average price of $1.94. Cognition Therapeutics, Inc. has a twelve month low of $1.07 and a twelve month high of $6.27. The company has a market capitalization of $45.68 million, a P/E ratio of -1.71 and a beta of 1.64.

About Cognition Therapeutics

(Get Rating)

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD).